Immutep Limited
NASDAQ:IMMPBiotechnology
+$0.00 today
- Market cap
- $55.01M
- Beta
- 2.24
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$0.06
Volume 3.10M
Average 13.46M
Returns on capital
Immutep Limited management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.8%
avg -59.6%
ROIC
-86.9%
avg -54.9%
ROA
-39.1%
avg -48.0%
Analysis
ROA is currently the strongest return metric at -39.1% versus its period average of -48.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Marc Voigt | Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director | AUD 610.1K | 53 | 0 | <0.01% |
Frederic Triebel | Chief Scientific Officer & Executive Director | AUD 504.27K | 71 | — | — |
Stephan Winckels | Chief Medical Officer | AUD 478.17K | — | — | — |
Deanne Miller | Chief Operating Officer, General Counsel & Joint Company Secretary | AUD 371.94K | 49 | — | — |
Christian Mueller | Chief Development Officer | AUD 279.68K | — | 0 | <0.01% |
Indira Naidu | Joint Company Secretary | — | — | — | — |
Compensation is shown in the reported currency; data updated Aug 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 1, 2028.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +209.4% | +76.1% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +209.4% over three years. Forward estimates point to Revenue at +76.1% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Immutep Limited compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about IMMP's management, answered from reported figures.
Who manages IMMP?
Immutep Limited (IMMP) lists 6 active executives. The top listed executive is Frederic Triebel, Chief Scientific Officer & Executive Director.
Are IMMP insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Continue the stock analysis
Jump to another research area for this company.